What do systematic reviews say?

Summary of findings 2: PLD alone vs other conventional chemotherapy

Summary of findings 2: PLD alone showed no clear difference in overall survival (OS) compared with other conventional chemotherapy (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.96 [0.77, 1.19]
  6 studies · 1995 participants
  Moderate

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Summary of findings 1: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with alternative combination chemotherapy (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.93 [0.83, 1.04]
  5 studies · 2006 participants
  Moderate

Summary of findings 1: PLD with chemotherapy vs PLD alone

Summary of findings 3: PLD with chemotherapy showed no clear difference in overall survival (OS) compared with PLD alone (moderate certainty).

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  HR 0.92 [0.7, 1.21]
  1 study · 242 participants
  Moderate

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy showed no clear difference in overall survival (OS) compared with placebo (maintenance therapy) (moderate certainty).

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  HR 0.81 [0.59, 1.13]
  2 studies · 1124 participants
  Moderate

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with chemotherapy (low certainty).

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  HR 0.95 [0.62, 1.47]
  2 studies · 331 participants
  Low

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in overall survival (OS) compared with placebo after chemotherapy (maintenance therapy) (moderate certainty).

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  HR 0.88 [0.65, 1.2]
  2 studies · 560 participants
  Moderate

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  GRADE not reported

Lifestyle interventions vs placebo or usual care

• Interventions for weight reduction in obesity to improve survival in women with endometrial cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2 participants
  Low

Lifestyle interventions vs placebo or usual care

It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes overall survival (24 months) compared with usual care compared to placebo (very low certainty).

• Interventions for weight reduction in obesity to improve survival in women with endometrial cancer 2023 · Cochrane Headline outcomes only
  RR 0.23 [0.01, 4.55]
  1 study · 37 participants
  Very low

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Platinum‐resistant recurrent EOC: PARPi monotherapy vs chemotherapy alone

The review found no eligible studies for this question.

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found